Previous 10 | Next 10 |
Gainers: XLRN +79.4% . SURF +17.2% . DESP +8.7% . KBWB +5.8% . BCRX +4.4% . More news on: Acceleron Pharma Inc., Surface Oncology, Inc., Despegar.com, Corp., Stocks on the move, , , News on ETFs Read more ...
Company focuses efforts and resources on advancing SRF617 and SRF388; Implements strategic restructuring Initial clinical updates for SRF617 and SRF388 expected by the end of 2020 Extends current cash runway into 2022 CAMBRIDGE, Mass., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Surfac...
Cancer drug company Forty Seven 's (NASDAQ: FTSV) stock price continues to climb higher following the December release of positive data from a Phase 1 clinical trial involving its lead cancer immunotherapy compound, magrolimab. The stock is up more than 200% since early last month. These...
Investment Thesis Last week, in my research note on direct Trillium (TRIL) rival, Forty Seven (FTSV), I argued that Forty Seven was the pick of the immunology companies developing CD47 antibodies to treat various forms of cancer - including hematologic malignancies, diffuse large B-cell ly...
Forty Seven Inc. (FTSV) had achieved positive results from an early-stage study in treatment-naive patients with high-risk myelodysplastic syndrome ((MDS)) and acute myeloid leukemia ((AML)). The positive results were obtained using the company's drug magrolimab in combination with Vidaza (a...
Dosing is underway in a Phase 2 registrational trial in China evaluating I-Mab Biopharma's TJ202/MOR202, a fully human monoclonal antibody targeting a protein found on the surface of cancer cells called CD38, in patients with relapsed/refractory multiple myeloma (MM). The company in-lice...
CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vito Palomb...
Surface Oncology ( SURF -22.3% ) secured a debt financing facility for up to $25M from K2 HealthVentures More news on: Surface Oncology, Inc., Healthcare stocks news, Read more ...
Gainers: JanOne (NASDAQ: JAN ) +103% . More news on: JanOne Inc., Sorrento Therapeutics, Inc., The Peck Company Holdings, Inc., Stocks on the move, Read more ...
CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced it has secured a debt financing facility for up to $25 mil...
News, Short Squeeze, Breakout and More Instantly...
Surface Oncology Inc. Company Name:
SURF Stock Symbol:
NASDAQ Market:
Surface Oncology Inc. Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Surface Oncology Inc. (SURF) is expected to report $-0.36 for Q3 2023
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both Institutional Shareholder Serv...